LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the completion of patient enrollment in the second of the company’s two phase III studies that comprise its global registrational program for Feraheme® (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause. The two phase III studies include one comparing treatment with Feraheme to placebo and one comparing treatment with Feraheme to treatment with intravenous iron sucrose. Both studies have now completed enrollment, with more than 1,400 patients enrolled through 210 study sites globally.
